Abstract
Purpose. The effect-plasma concentration relationship of etomidate was studied in the rat using electroencephalographic changes as a pharmacodynamic parameter.
Methods. Etomidate was infused (50 mg/kg/h) in chronically instrumented rats (n = 6) until isoelectric periods of 5 s or longer were observed in the electroencephalogram (EEG). The EEG was continuously recorded during the experiment and frequent arterial blood samples were taken for determination of etomidate plasma concentrations. The changes observed in the raw EEG signal were quantified using aperiodic analysis in the 2.5−7.5 Hz frequency band. The return of the righting reflex was used as another parameter of anesthesia.
Results. A mean dose of 8.58 ± 0.41 mg/kg needed to be infused to reach the end point of 5 s isoelectric EEG. The plasma concentration time profiles were most adequately fitted using a three-exponential model. Systemic clearance, volume of distribution at steady-state and elimination half-life averaged 93 ± 6 ml/min/kg, 4.03 ± 0.24 l/kg and 59.4 ± 10.7 min respectively. The EEG effect-plasma concentration relationship was biphasic exhibiting profound hysteresis. Semi-parametric minimization of this hysteresis revealed an equilibration half-life of 2.65 ± 0.15 min, and the biphasic effect-concentration relationship was characterized nonparametrically by descriptors. The effect-site concentration at the return of the righting reflex was 0.44 ± 0.03 μg/ml.
Conclusions. The results of the present study show that the concentration-effect relationship of etomidate can be characterized in individual rats using aperiodic analysis in the 2.5−7.5 Hz frequency band of the EEG. This characterization can be very useful for studying the influence of diseases on the pharmacodynamics of etomidate in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
T. J. Ebert, M. M. Muzi, R. Berens, D. Goff, and J. P. Kampine. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology 76:725–733 (1992).
M. P. Colvin, T. M. Savege, P. E. Newland, E. J. Weaver, A. F. Waters, J. M. Brookes, and R. Inniss. Cardiorespiratory changes following induction of anaesthesia with etomidate in patients with cardiac disease. Br. J. Anaesth. 51:551–556 (1979).
B. Simon and G. P. Young. Emergency airway management. Acad. Emerg. Med. 1:154–157 (1994).
J. W. Mandema and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. J. Pharmacokin. Biopharm. 18:459–481 (1990).
F. W. Ossenberg, M. Peignoux, D. Bourdiau, and J. P. Benhamou. Pentobarbital pharmacokinetics in the normal and in the hepatectomized rat. J. Pharmacol. Exp. Ther. 194:111–116 (1975).
P. Le Moing and J. C. Levron. High-performance liquid chromatographic determination of etomidate in plasma. J. Chromatogr. 529:217–222 (1990).
F. M. Belpaire and M. G. Bogaert. Binding of diltiazem to albumin, α1-acid glycoprotein and to serum in man. J. Clin. Pharmacol. 30:311–317 (1990).
H. Akaike. A new look at the statistical model identification. IEEE Trans. Automat. Control AC 19:716–723 (1974).
M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, 1982.
T. K. Gregory and D. C. Pettus. An electroencephalographic processing algorithm specifically intended for analysis of cerebral electrical activity. J. Clin. Monit. 2:190–197 (1986).
D. Verotta and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics: An improved algorithm. CAB-IOS 3:345–349 (1987).
W. F. Ebling, M. Danhof, and D. R. Stanski. Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats. J. Pharmacokin. Biopharm. 19:123–143 (1991).
D. J. De Wildt, F. C. Hillen, A. G. Rauws, and B. Sangster. Etomidate-anaesthesia, with and without fentanyl, compared with urethane-anaesthesia in the rat. Br. J. Pharmacol. 79:461–469 (1983).
J. M. Gooding and G. Corssen. Effect of etomidate on the cardiovascular system. Anesth. Analg. 56:717–719 (1977).
J. Schüttler, H. Schwilden, and H. Stoeckel. Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: Etomidate as an example. Eur. J. Anaesth. 2:133–142 (1985).
K. Fruergaard, M. Jenstrup, J. Schierbeck, and F. Wiberg-Jorgensen. Total intravenous anaesthesia with propofol or etomidate. Eur. J. Anaesth. 8:385–391 (1991).
L. L. Gustafsson, W. F. Ebling, E. Osaki, and D. R. Stanski. Quantitation of depth of thiopental anesthesia in the rat. Anesthesiology 84:415–427 (1996).
A. Wauquier, W. A. E. Van Den Broeck, J. L. Verheyen, and P. A. J. Janssen. Electroencephalographic study of the short-acting hypnotics etomidate and methohexital in dogs. Eur. J. Anaesth. 47:367–377 (1978).
M. M. Ghoneim and T. Yamada. Etomidate: A clinical and electroencephalographic comparison with thiopental. Anesth. Analg. 56:479–485 (1977).
A. Doenicke, B. Löffler, J. Kugler, H. Suttmann, and B. Grote. Plasma concentration and EEG after various regimens of etomidate. Br. J. Anaesth. 54:393–400 (1982).
J. R. Arden, F. O. Holley, and D. R. Stanski. Increased sensitivity to etomidate in the elderly: Initial distribution versus altered brain response. Anesthesiology 65:19–27 (1986).
S. Dutta, Y. Matsumoto, N. U. Gothgen, and W. F. Ebling. Concentration-EEG effect relationship of propofol in rats. J. Pharm. Sci. 86:37–43 (1997).
S. Dutta and W. F. Ebling. Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. J. Pharm. Pharmacol. 50:37–42 (1998).
E. H. Cox, C. A. J. Knibbe, V. S. Koster, M. W. E. Langemeijer, E. E. Tukker, R. Lange, P. F. M. Kuks, H. J. M. Langemeijer, L. Lie-A-Huen, and M. Danhof. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm. Res. 15:442–448 (1998).
A. G. De Boer and D. D. Breimer. Rectal, oral and I.A. administration of etomidate to rats: Significant avoidance of hepatic first-pass elimination following rectal administration. Arch. Int. Pharmacodyn. Ther. 270:180–191 (1984).
M. S. Yates, C. R. Hiley, P. J. Roberts, D. J. Back, and F. E. Crawford. Differential effects of hepatic microsomal enzyme inducing agents on liver blood flow. Biochem. Pharmacol. 27:2617–2621 (1978).
P. J. Lewi, J. J. P. Heykants, and P. A. J. Janssen. Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug. Arch. Int. Pharmacodyn. Ther. 220:72–85 (1976).
W. E. G. Meuldermans and J. J. P. Heykants. The plasma protein binding and distribution of etomidate in dog, rat and human blood. Arch. Int. Pharmacodyn. Ther. 221:150–162 (1976).
J. W. Mandema, P. Veng-Pedersen, and M. Danhof. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. J. Pharmacokin. Biopharm. 19:617–634 (1991).
J. J. P. Heykants, W. E. G. Meuldermans, L. J. M. Michiels, P. J. Lewi, and P. A. J. Janssen. Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of R-(+) and S-(−)-etomidate. Arch. Int. Pharmacodyn. Ther. 216:113–129 (1975).
H. Schwilden, J. Schüttler, and H. Stoeckel. Quantitation of the EEG and pharmacodynamic modelling of hypnotic drugs: Etomidate as an example. Eur. J. Anaesth. 2:121–131 (1985).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Paepe, P., Van Hoey, G., Belpaire, F.M. et al. Relationship Between Etomidate Plasma Concentration and EEG Effect in the Rat. Pharm Res 16, 924–929 (1999). https://doi.org/10.1023/A:1018894523734
Issue Date:
DOI: https://doi.org/10.1023/A:1018894523734